RE:RE:Biotech industry readies for " Pharma M&A Spree" The recent push to plug patent-loss gaps by Big Pharma has left fewer late-stage biotechs available for Big Pharma to scoop up, so there are more deals around earlier-stage companies and assets. The result is that these late-stage biotech companies and assets will be acquired at significant M&A premiums, from where they may currently trade, particularly if those companies and their assets align with the acquirers' core product pipeline and key assets.
As we know, ONCY is a late-stage clinical development company in which the company has been advancing the clinical development of pelareorep for the treatment of varius cancers with unmet medical treatment needs.
As outlined in numerous posts here, ONCY's pelareorep can both enhance the effectiveness of many Big Pharma currently marketed blockbuster products, as well as being able to extend their marketing exclusivity beyond their patent expirations, if combined with pelareorep and creating new I/O therapy, due to the FDA's 13 years of market exclusivity for novel biologic drugs that have not been previously approved, such as those like ONCY's pelareorep
ONCY has currently pursued treatment in 5 cancers involving 7 treatment modalities - from the use of pelareorep as a monotherapy to that in combination with other cancer agents.